Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Representative image: A clinician uses an energy-based laser device in a modern dermatology clinic, reflecting how Lumenis’ ASLMS clinical data could strengthen evidence-led treatment pathways for hair loss, rhinophyma and skin rejuvenation in medical aesthetics.
Medical Devices & Diagnostics

Lumenis strengthens FoLix, ULTRApulse Alpha and Stellar M22 case with ASLMS data

Aesthetics needs stronger evidence. Lumenis is using ASLMS data to push lasers deeper into hair loss, skin and rhinophyma care.

Read More
Pharma & Biotech

How Zifo’s AI authoring platform could reshape clinical and CMC documentation

Regulatory teams need speed, but AI needs auditability. Zifo’s authoring platform tests whether pharma can have both.

Read More
Representative image: INOVIO Pharmaceuticals’ upcoming ASCO and ASGCT conference posters place INO-3107 DNA immunotherapy and early hemophilia A gene transfer research under the spotlight as investors watch the biotech firm’s regulatory and platform strategy.
Pharma & Biotech

INOVIO’s ASCO and ASGCT updates may sharpen scrutiny of its DNA medicine strategy

INOVIO has a regulatory clock ticking. New INO-3107 and hemophilia A data may show whether its DNA platform can move beyond promise.

Read More
Pharma & Biotech

Pharma has a Hispanic engagement problem. Relevant+ thinks Healthy Vibras can fix it

Hispanic health trust is still uneven. Healthy Vibras tests whether culture-first media can change pharma engagement.

Read More
Representative image: Soligenix’s HyBryte trial setback has shifted investor and industry attention toward rare disease pipeline priorities, cash runway, and the future of SGX945 in Behçet’s disease.
Pharma & Biotech

What Soligenix’s Q1 update reveals about biotech risk after a failed confirmatory trial

HyBryte’s setback leaves Soligenix with cash, orphan assets, and a harder question. Can SGX945 reset the rare disease story?

Read More
Representative image of a biopharmaceutical laboratory workflow showing HEK293 functional cell line research, assay development and compliance documentation, as ACROBiosystems streamlines global licensing access to support faster drug discovery and regulated R&D operations.
Pharma & Biotech

ACROBiosystems makes HEK293 functional cell lines easier to use in global R&D workflows

HEK293 tools are everywhere, but licensing slows teams down. ACROBiosystems is turning compliance clarity into an R&D advantage.

Read More
Representative image of berberine-infused natural GLP-1 supplements with botanical ingredients and healthy food cues, reflecting PureHealth Research’s push into metabolic wellness, satiety support, and the fast-growing consumer health market for natural GLP-1 alternatives.
Pharma & Biotech

Why PureHealth Research’s berberine GLP-1 supplement push enters a crowded evidence debate

GLP-1 demand is reshaping supplements. PureHealth Research’s berberine launch tests where wellness claims meet evidence and regulation.

Read More
Representative image: Oncology researchers reviewing head and neck cancer imaging data, reflecting the clinical focus of Inhibrx Biosciences’ INBRX-106 HexAgon study update in first-line HNSCC and the broader immuno-oncology race to improve pembrolizumab-based treatment strategies.
Pharma & Biotech

Inhibrx’s HexAgon study may test whether smarter OX40 design can beat old failures

OX40 biology has promised more than it proved. Inhibrx now needs INBRX-106 to show pembrolizumab can work harder in HNSCC.

Read More
Representative image: Advanced lung cancer research and oncology treatment planning are becoming central to the debate over whether Kelun-Biotech’s sacituzumab tirumotecan and pembrolizumab combination can reshape first-line NSCLC care.
Pharma & Biotech

Why Kelun-Biotech’s sac-TMT review could reshape China’s lung cancer ADC market

ADC ambition meets Keytruda dominance. Kelun-Biotech’s sac-TMT filing could test how far TROP2 combinations can move in lung cancer.

Read More
KUBTEC Scientific’s XCELL TomoRad targets a major bottleneck in preclinical radiotherapy studies
Medical Devices & Diagnostics

Can KUBTEC Scientific lower the barrier to image-guided radiotherapy in cancer research?

Preclinical IGRT is powerful but costly. KUBTEC Scientific’s XCELL TomoRad tests whether access, speed, and targeting can finally align.

Read More